Closed · W81XWH-15-NETPR-DRA · CFDA 12.420 · Discretionary

Neurotoxin Exposure Treatment Parkinson's Depression Research Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
December 16, 2015
Close date
1
Expected awards

The verdict

Neurotoxin Exposure Treatment Parkinson's Depression Research Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
1
expected award
12.420
CFDA program

Archived opportunity record

Neurotoxin Exposure Treatment Parkinson's Dep… is closed (last close December 16, 2015). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed December 16, 2015

Posted Oct 22 Closes Dec 16

Est. Total Funding

$2,500,000

Expected Awards

1

Instrument

Grant

Description

Applications to the Fiscal Year 2015 (FY15) Neurotoxin Exposure Treatment Parkinson’s Research (NETPR) program are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The executing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP). The NETPR was initiated in FY97 to provide support for research of exceptional scientific merit leading to an understanding of the cause, prevention, and treatment of the loss of dopaminergic neurons in the Substantia nigra that result in Parkinson’s disease (PD). The mission of the NETPR Program is to: · Identify surrogate markers of PD, · Correlate distinctive clinical features with specific clusters of these markers, and · Develop interventions in bio-molecular pathways that link markers and expressed clinical features in order to prevent or halt progression of the disease or improve the quality of life for PD patients. Depression is both an epidemiological identified risk factor for development of PD and a co-morbid condition that affects an increasing proportion of individuals as PD progresses. This funding opportunity is specifically focused on the following Areas of Emphasis on depression as a risk factor and/or co-morbidity in PD: · Delineation of metabolic pathways that may lead to identification of molecular markers and/or therapeutic targets associated with modulation or control of serotonergic or non¬serotonergic activity. · Characterization of underlying genetic mechanisms associated with development of depression, or characterization of intersects between genetic mechanisms associated with depression and other known risk factors (as identified in published literature) for development of PD. · Identification of surrogate markers in the blood for identification, diagnosis, susceptibility, maintenance, or progression of depression associated with neurodegeneration. Innovative applications not focused on the Areas of Emphasis noted above are acceptable, provided the application: · Is specifically related to development or progression of depression as a non-motor manifestation of PD and/or is clearly linked to depression as a risk factor for initiation or progression of PD; and · Provides a strong rationale for relevance to the mission of the NETPR Program. The Depression Research Award mechanism is being offered for the first time in FY15. The intent of the NETPR Depression Research Award is to support research efforts that will make significant advancements in the understanding of serotonergic and non-serotonergic molecular pathways identified with depression and associated biologic phenomena that link the pathways to other risk factors (e.g., disruption of sleep architecture, exposure to long-term psychological and physiological stress, dysautonomia, and traumatic brain injury) for development and progression of PD. It is expected that research supported by this award will lead to the development of new treatments or the improvement of current treatments for depression, specifically in individuals with, or at risk for, PD. It is anticipated that projects will emphasize preclinical research in human populations, animal studies, or in silico retrospective studies. Preliminary data are required.

Catch-all / unrestricted eligibility mark · W81XWH-15-NETPR-DRA

Grants.gov marks Neurotoxin Exposure Treatment Parkinson's Dep… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

301-682-5507; help@cdmrp.org

What to do next

Neurotoxin Exposure Treatment Parkinson's Dep… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants